Profusa, Inc. (NASDAQ: PFSA)

NorthView Acquisition Corp (NVAC) operates in the healthcare innovation industry, focusing on small-cap companies in North America, Europe, and the APAC regions that are developing assets in the biopharmaceutical, medical technology/medical device, and diagnostics space. The company was founded on April 19, 2021, and is a blank check company that intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

NVAC's primary business activities revolve around identifying and acquiring target businesses in the healthcare innovation industry. The company is focused on four key segments within the industry, including the biopharmaceutical, medical technology/device, diagnostics, and healthcare innovation segments. These segments represent a significant portion of the healthcare innovation industry, and NVAC believes that its management team and directors have the necessary experience and expertise to evaluate and acquire companies in these areas.

The company generates revenue through the acquisition of a target business, which is determined through a thorough due diligence review. As a blank check company, NVAC does not have any current operations or specified primary products and services. However, the company's management team and directors have extensive experience in operating healthcare companies and developing drug and device technology.

NVAC believes that its competitive advantages include its high-quality management team with extensive operational, financial, merger and acquisition, and public company experience, as well as its resources and expertise in evaluating and acquiring target businesses. The company's management team and directors have a deep understanding of the healthcare industry and have established relationships with various healthcare companies, which may provide a competitive advantage in identifying and acquiring target businesses.

The company's initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the trust account. Public stockholders of NVAC have the right to redeem their shares for a pro rata share of the trust account, which will be held in escrow pending the completion of the company's initial business combination.

NVAC's initial stockholders, officers, directors, and/or their affiliates may also purchase shares from public stockholders who have elected to redeem their shares, subject to certain restrictions and requirements. If NVAC is unable to complete its initial business combination within the combination period, it will cease all operations except for the purpose of winding up, redeem the public shares, and dissolve and liquidate. The company's initial stockholders have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares if NVAC fails to complete its initial business combination within the combination period.